Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sotac Pharmaceuticals's Enterprise Value is ₹1,472.0 Mil.
Sotac Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹89.7 Mil. Therefore, Sotac Pharmaceuticals's EV-to-FCF for today is 16.41.
The historical rank and industry rank for Sotac Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NSE:SOTAC'
s EV-to-FCF Range Over the Past 10 Years
Min: -214.54 Med: -8.45 Max: 19.1
Current: 17.01
During the past 7 years, the highest EV-to-FCF of Sotac Pharmaceuticals was 19.10. The lowest was -214.54. And the median was -8.45.
NSE:SOTAC's EV-to-FCF is ranked better than 60.39% of 563
companies
in the Drug Manufacturers industry
Industry Median: 21.03
vs NSE:SOTAC: 17.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sotac Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Sotac Pharmaceuticals's share price for today is ₹95.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sotac Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's EV-to-FCF falls into.
Sotac Pharmaceuticals's current Enterprise Value is ₹1,472.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sotac Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹89.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a EV-to-FCF of 16.41 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sotac Pharmaceuticals and its competitors. According to the industry distribution chart, Sotac Pharmaceuticals ranks #223 out of 563 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Sotac Pharmaceuticals' EV-to-FCF too high?
Sotac Pharmaceuticals' current EV-to-FCF is 16.41. The Drug Manufacturers industry median EV-to-FCF is 21.03. Sotac Pharmaceuticals' value of 16.41 is 22% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #223 out of 563 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #223 out of 563 companies for EV-to-FCF. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 21.03. Sotac Pharmaceuticals' value of 16.41 is 22% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.03, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current EV-to-FCF of 16.41 is 22% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sotac Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current EV-to-FCF is 16.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹140.86, compared to a current price of ₹95.10 — trading 32.5% below its estimated fair value. The current EV-to-FCF is 16.41 and 22% below the Drug Manufacturers industry median of 21.03. Sotac Pharmaceuticals' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current EV-to-FCF is 16.41 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹95.10 is trading 32.5% below its estimated GF Value™ of ₹140.86.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
EV-to-FCF: 16.41
GF Value™: ₹140.86 vs. price of ₹95.10 (32.5% below fair value)
Industry Position: 22% below the Drug Manufacturers median (#223 of 563)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
58GF Score
Get the complete analysis for NSE:SOTAC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
